Japanese media: As soon as next July, glasses that can treat myopia will be available

Myopia is mostly caused by the elongation of the distance from the cornea to the retina and the deviation of the focus, while there are more myopia patients in Asia. According to the Nikkei Chinese network reported on December 31, the Japanese company that develops ophthalmic therapeutic drugs and devices, Kata Pharmaceutical, said that it will start selling eyeglass-shaped products for the treatment of myopia as early as the second half of 2021. When worn, the glasses project the company's self-developed images onto the retina to correct focus deviations.

According to reports, this eyeglass for the treatment of myopia, through the lens for the treatment of the image projected into the patient's eye, and the patient will not be aware of the projected image, so can be treated while carrying out daily activities. Patients should wear it for 1 hour to 1 and a half hours a day. For the specific principle, Yutian Pharmaceutical has not publicly stated.

The effect of this glasses has been confirmed by testing with benchtop equipment and has been in clinical trials of spectacle-type devices since July. At present, Ryota Pharmaceutical is conducting clinical trials on about 25 people in the United States to verify the effectiveness of treatment.

Ryo Kata, president of the company, said that he "hopes to sell it first in Asia, which has a high rate of myopia," and is exploring sales in countries such as Thailand and Malaysia.

Regulations vary from country to country as to whether eyewear is a medical device. Yuta pharmaceutical said that while communicating with relevant departments in various countries, it is possible to promote development and may be sold as ordinary glasses. In addition, the company is developing contact lens-type devices.